Skip to main content
main-content

28.07.2017 | ORIGINAL ARTICLE | Ausgabe 3/2017

Cardiovascular Drugs and Therapy 3/2017

Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study

Zeitschrift:
Cardiovascular Drugs and Therapy > Ausgabe 3/2017
Autoren:
Véronique Ferchaud-Roucher, Mikaël Croyal, Thomas Moyon, Yassine Zair, Michel Krempf, Khadija Ouguerram
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10557-017-6737-y) contains supplementary material, which is available to authorized users.

Abstract

Background

Plasma high triacylglycerols and low HDL-C concentration are associated with increased cardiovascular events. Extended-release nicotinic acid (ERN) was shown to reduce plasma triacylglycerols and total cholesterol but also to markedly increase high-density lipoprotein-cholesterol (HDL-C). No data on the effect of ERN on different species of triacylglycerol, cholesteryl ester, and phospholipids are available. In this study, we applied a nontargeted lipidomic approach to investigate the plasma and lipoproteins lipids profile of hypertriglyceridemic patients treated with ERN or a placebo in order to identify new lipids markers associated with this treatment.

Methods

Eight hypertriglyceridemic patients enrolled in a crossover randomized trial with ERN for 8 weeks and treated with 2 g/day of ERN or a placebo. Ultra-performance liquid chromatography (UPLC) coupled to high-resolution mass spectrometry (HRMS) was used in mass spectrometry energy mode (HRMSE) combined with ion mobility spectrometry to characterize the plasma and very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) lipidome. The accuracy and precision of the method were validated on plasma samples.

Results

Compared to placebo, among 155 plasma lipids characterized using UPLC-ESI-HRMS, a multivariate analysis revealed a significant increase of lysophosphatidylcholine (LPC 20:5), a significant decrease of phosphatidylethanolamine (PE 16:0/22:3) and sphingomyelin (SM d18:1/22:0) and a decrease of triacylglycerol (TG 16:0/16:1/18:2) after ERN treatment. Analysis of these lipids in lipoproteins showed an increase of LPC (20:5) in HDL, a decrease of PE (16:0/22:3) in HDL and LDL, of SM (d18:1/22:0) in VLDL and LDL and of TG (16:0/16:1/18:2) in VLDL.

Conclusion

This lipidomic strategy characterized new specific lipid markers likely to be involved in the effect of ERN on cardiovascular risk opening a new strategy to analyze randomized controlled with this treatment.

Trial Registration

NCT01216956

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Table S1 List of lipids identified in the plasma samples of the hypertriglyceridemic subjects. (DOC 45 kb)
10557_2017_6737_MOESM1_ESM.doc
Table S2 Details of lipids characterization identified in plasma of the hypertriglyceridemic patients. (DOC 136 kb)
10557_2017_6737_MOESM2_ESM.doc
Table S3 Spearman’s correlation between the four significant lipid markers and clinical parameters. Differences between niacin and placebo treatment were considered statistically significant after a p-value correction based on the false discovery rate (FDR) using the q-value concept with a significance threshold set at q ≤ 0.05. (DOC 80 kb)
10557_2017_6737_MOESM3_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

Cardiovascular Drugs and Therapy 3/2017 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise